EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	icotinib + furmonertinib Sensitive: C3 – Early Trials ELCC 2023 - 1 week (New C3) icotinib + furmonertinib Sensitive : C3 ELCC 2023 - 1wk	icotinib + furmonertinib Sensitive: C3 – Early Trials ELCC 2023 - 1 week icotinib + furmonertinib Sensitive : C3 ELCC 2023 - 1 week - (New C3)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	TY-4028 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) TY-4028 Sensitive : D AACR 2023 - 2wk	TY-4028 Sensitive: D – Preclinical AACR 2023 - 2 weeks TY-4028 Sensitive : D AACR 2023 - 2 weeks - (New D)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: A1 - Approval mobocertinib Sensitive : A1	mobocertinib Sensitive: A1 - Approval mobocertinib Sensitive : A1
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	CLN-081 Sensitive: B - Late Trials CLN-081 Sensitive : B	CLN-081 Sensitive: B - Late Trials CLN-081 Sensitive : B
EGFR exon 20 insertion	Lung Non-Small Cell Squamous Cancer	EGFR exon 20 insertion	Lung Non-Small Cell Squamous Cancer	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	DZD9008 Sensitive: B - Late Trials DZD9008 Sensitive : B	DZD9008 Sensitive: B - Late Trials DZD9008 Sensitive : B
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	cetuximab + afatinib Sensitive: C2 – Inclusion Criteria cetuximab + afatinib Sensitive : C2	cetuximab + afatinib Sensitive: C2 – Inclusion Criteria cetuximab + afatinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	osimertinib Sensitive: C2 – Inclusion Criteria osimertinib Sensitive : C2	osimertinib Sensitive: C2 – Inclusion Criteria osimertinib Sensitive : C2
EGFR exon 20 insertion	Solid Tumor	EGFR exon 20 insertion	Solid Tumor	BDTX-189 Sensitive: C2 – Inclusion Criteria BDTX-189 Sensitive : C2	BDTX-189 Sensitive: C2 – Inclusion Criteria BDTX-189 Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	erlotinib Resistant: C2 – Inclusion Criteria erlotinib Resistant : C2	erlotinib Resistant: C2 – Inclusion Criteria erlotinib Resistant : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	furmonertinib Sensitive: C2 – Inclusion Criteria furmonertinib Sensitive : C2	furmonertinib Sensitive: C2 – Inclusion Criteria furmonertinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: C3 – Early Trials cisplatin + pemetrexed Sensitive : C3	cisplatin + pemetrexed Sensitive: C3 – Early Trials cisplatin + pemetrexed Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	Platinum alkylating agent Sensitive: C3 – Early Trials Platinum alkylating agent Sensitive : C3	Platinum alkylating agent Sensitive: C3 – Early Trials Platinum alkylating agent Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	anlotinib + sintilimab Sensitive: C3 – Early Trials anlotinib + sintilimab Sensitive : C3	anlotinib + sintilimab Sensitive: C3 – Early Trials anlotinib + sintilimab Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3	Angiogenesis inhibitor Sensitive: C3 – Early Trials Angiogenesis inhibitor Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3
EGFR exon 20 insertion	Lung Adenocarcinoma	EGFR exon 20 insertion	Lung Adenocarcinoma	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	ABCP Sensitive: C3 – Early Trials ABCP Sensitive : C3	ABCP Sensitive: C3 – Early Trials ABCP Sensitive : C3
EGFR exon 20 insertion	Lung Adenocarcinoma	EGFR exon 20 insertion	Lung Adenocarcinoma	bevacizumab Sensitive: C4 – Case Studies bevacizumab Sensitive : C4	bevacizumab Sensitive: C4 – Case Studies bevacizumab Sensitive : C4
EGFR exon 20 insertion	Lung Adenocarcinoma	EGFR exon 20 insertion	Lung Adenocarcinoma	osimertinib Resistant: C4 – Case Studies osimertinib Resistant : C4	osimertinib Resistant: C4 – Case Studies osimertinib Resistant : C4

EGFR exon 20 insertion

Associations